Get the latest Science News and Discoveries

How Eli Lilly’s new GLP‑1 pill stacks up against Wegovy and other weight‑loss drugs

This week the U.S. Food and Drug Administration approved a second GLP-1 pill for weight loss. The drug, called Foundayo, resulted in an average of 27 pounds lost in 72 weeks

None

Get the Android app

Or read this on Scientific American

Related news:

New Drug Could Help Maintain Weight Loss After Ozempic and Wegovy

Wegovy may have highest eye stroke and sight loss risk of semaglutide GLP-1 agonists— Odds of ischaemic optic neuropathy(caused by inadequate/interrupted blood flow to the optic nerve, resulting in sudden vision loss in one or both eyes) nearly 5 times higher than among users of Ozempic

Sudden Sight Loss Risk Almost 5x Higher With Wegovy Than Ozempic, Study Finds

« ‘Jaw-dropping’ fossils reset the clock on when complex animals evolved

Octopus sex is even weirder than you think »